Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Padagis Achieves A US First With Budesonide Foam Launch

Rival To Uceris Rectal Foam Benefits From 180 Days Of CGT Exclusivity

Executive Summary

Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.

You may also be interested in...



Padagis Seeks To Challenge Hikma’s Kloxxado

Padagis has set out two first-to-file ANDA submissions in the US, challenging Hikma’s Kloxxado as well as Evofem’s Phexxi. The former Perrigo Rx business has also just launched two limited-competition generics.

ANI Aims For CGT Top Spot With Two New Launches

ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.

Who's Hired? Padagis Gets New Leadership

Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel